Clinical High Risk Psychosis: Issues of Diagnostics and Therapy

The aim of the review: the analysis of modern Russian and foreign literature dedicated to the problem of determining diagnostic criteria for clinical high risk of psychosis (CHR-P) and outlining the therapeutic approaches based on the pathogenic mechanisms of their development. Material and method: the publications found by searching queries for keywords in Russian and English in the MEDLINE/PubMed and eLIBRARY databases for the time period from 2010 to 2020 were then analyzed. Conclusion: the review presents a modern definition of the CHR-P group, along with a clarification of individual diagnostic criteria, which include attenuated psychotic symptoms (APS), brief limited intermittent psychotic symptoms (BLIPS), genetic risk with deterioration of premorbid functioning, as well as basic symptoms (BS). We found heterogeneity of the CHR-P group with different levels of manifestation and outcomes and indicated the involvement of different pathogenic mechanisms in their formation. These findings determine the development of various approaches to treatment, which involve the assessment of the ratio of potential benefits and the risks of side effects. The obtained data, on the one hand, attest to the prospective viability of the therapeutic approach to the patients with CHR-P with the possibility of influencing the course of the disease, delaying its manifestation and improving long-term outcomes, and, on the other hand, the lack of universal standards of therapy at present. Tactics of treatment are determined basing on an individual approach to the patient with a comprehensive psychopathological assessment of complaints, clinical state and its dynamics.

1. Kaleda VG, Omelchenko MA, Rumyantsev AO. Psychotic risk in a young age. Zhurnal Psihiatriya i psihofarmakoterapiya imtni P.B. Gannushkina. 2017;19(2):27–33. (In Russ.). eLIBRARY ID: 29909882

2. Nelson B, Amminger G, McGorry P. Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research. Front Psychiatry. 2018;9:502 https://DOI.org/10.3389/fpsyt.2018.00502

3. Kaleda VG, Omel’chenko MA, Sergeeva OE, Golimbet VE, Rumyancev AO. Domanifestnyj etap yunosheskih endogennyh pristupoobraznyh psihozov i problema vyyavleniya faktorov riska ih manifestacii. XVI S’ezd psihiatrov Rossii. Vserossijskaya nauchno-prakticheskaya konferenciya s mezhdunarodnym uchastiem «Psihiatriya na etapah reform: problemy i perspektivy», Kazan’. 2015;969–970. (In Russ.). eLIBRARY ID: 27650128

4. Mazaeva NA, Golovina AG. Early onset schizophrenia: Targets of psychoeducation. Consciousness. 2019;21(10):47–53. (In Russ.). http://dx.DOI.org/10.26787/nydha-2686-6846-2019-21-10-47-53

5. Addington J, Goldshtein B, Wang J, Kennedy S, Bray S, Lebel C, Hesse S, Marshall C, MacQueen G. Youth at-risk for serious mental illness: Methods of the PROCAN study. BMC Psychiatry. 2018:18(1):219. http://dx.DOI.org/10.1186/s12888-018-1801-0

6. Kline E, Seidman L, Cornblatt B, Woodberry K, Bryant C, Bearden C, Cadenhead K, Cannon T, Mathalon D, McGlashan T, Perkins D, Tsuang M, Walker E, Woods S, Addington J. Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr. Res. 2018;192:357–363. https://DOI.org/10.1016/j.schres.2017.05.032

7. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet Lond. Engl. 2011;377:2093–2102. https://DOI.org/10.1016/S0140-6736(11)60512-6

8. Fusar-Poli P. The Clinical High-Risk State for Psychosis (CHR-P), Version II. Schizophr. Bull. 2017;43(1):44-47. https://DOI.org/10.1093/schbul/sbw158

9. Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson DR, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C, Weinberger D. Altering the course of schizophrenia: progress and perspectives. Nat Rev. Drug Discov. 2016;15:485–515. https://DOI.org/10.1038/nrd.2016.28

10. Oliver D, Davies C, Crossland G, Lim S, Gifford G, McGuire P, Fusar-Poli P. Can we reduce the duration of untreated psychosis? A meta-analysis of controlled interventional studies. Schizophr. Bull. 2018;44(6):1362–1372. https://DOI.org/10.1093/schbul/sbx166

11. Andreou C, Bailey B, Borgwardt S. Assessment and treatment of individuals at high risk for psychosis. B.J. Psych. Advances. 2019;25(3):177–184. https://DOI.org/10.1192/bja.2019.3

12. Fusar-Poli P, Cappucciati M, De Micheli A, Rutigliano G, Bonoldi I, Tognin S, Ramella-Cravaro V, Castagnini A, McGuire P. Diagnostic and prognostic significance of brief limited intermittent psychotic symptoms (BLIPS) in individuals at ultra high risk. Schizophr. Bull. 2017;43:48–56. https://DOI.org/10.1093/schbul/sbw151

13. Sergeeva OE, Kaleda VG, Golimbet VE. K voprosu o vyyavlenii v podrostkovo-yunosheskom vozraste gruppy vysokogo riska manifestaci iendogennyh psihozov (psihopatologicheskie i molekulyarno-geneticheskie aspekty). Psychiatry. 2014;3(63):59–59. (In Russ.). eLIBRARY ID: 23113218

14. Golimbet VE, Korovajtseva GI, Lezhejko TV, Kaleda VG, Abramove LI, Gabaeva MV. Method for predicting risk of schizophrenia. Patent for invention. RU 2548784 C1. Bull 11.20.04.2015. (In Russ.). eLIBRARY ID: 37429920

15. Falkenberg I, Valmaggia L, Byrnes M, Frascarelli, Jones C, Rocchetti M, Straube B, Badger S, McGuire P, Fusar–Poli P. Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? Psychiatry Res. 2015;228(3):808–815. https://DOI.org/10.1016/j.psychres.2015.05.018

16. Skuhareuskaya MM. Attenuated psychosis syndrome as a new diagnosis in psychiatry? Psihiatriya i psihofarmakoterapiya imeni P.B. Gannushkina. 2014;02:40–43. (In Russ.). eLIBRARY ID: 21618132

17. Aleshkina G.A., Bardenshtein L.M., Pugacheva M.E., Kononec A.S. Acute brief psychotic schizophrenia spectrum disorders (review of literature). Psikhi cheskoe zdorovie. 2019;(11):51–64. (In Russ.). https://DOI.org/10.25557/2074-014X.2019.11.51-64

18. Rumyantsev AO, Omel‘chenko MA, Kaleda VG. Attenuated psychotic symptoms in the structure of youth depression (clinical and psychopathological aspects). Russian journal of psychiatry. 2018;1:61–70. (In Russ.). eLIBRARY ID: 32636653

19. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.

20. Schultze-Lutter F, Theodoridou A. The concept of basic symptoms: its scientific and clinical relevance World Psychiatry. 2017;16(1):104–105. https://DOI.org/10.1002/wps.20404

21. Neznanov NG, Kotsubinsky AP, Mazo GE. Biopsycho-social concept of mental disorders as a basis for cholistic diagnostic approach. Part 1. Social’naya i klinicheskaya psihiatriya. 2018;28(3):62–67. (In Russ.). eLIBRARY ID: 36693858

22. Schultze–Lutter F, Debbané M, Theodoridou A, Wood SJ, Raballo A, Michel C, Schmidt SJ, Kindler J, Ruhrmann S, Uhlhaas PJ. Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets. Front Psychiatry. 2016;7:9. https://DOI.org/10.3389/fpsyt.2016.00009

23. Parnas J. The core Gestalt of schizophrenia. World Psychiatry. 2012;11(2):67–69. https://DOI.org/10.1016/j.wpsyc.2012.05.002

24. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, Nieman DH, Stahl DR, Rutigliano G, Riecher–Rössler A, Simon AE, Mizuno M, Lee TY, Kwon JS, Lam MM, Perez J, Keri S, Amminger P, Metzler S, Kawohl W, Rössler W, Lee J, Labad J, Ziermans T, An SK, Liu CC, Woodberry KA, Braham A, Corcoran C, McGorry P, Yung AR, McGuire PK. Heterogeneity of psychosis risk within individuals at clinical high risk. JAMA Psychiatry. 2016;73:113–20. https://DOI.org/10.1001/jamapsy-chiatry.2015.2324

25. Schimmelmann BG, Michel C, Martz–Irngartinger A, Linder C, Schultze-Lutter F. Age matters in the prevalence and clinical significance of ultra-highrisk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychiatry Off. J. World Psychiatr. Assoc WPA. 2015;14:189–97. https://DOI.org/10.1002/wps.20216

26. Mazaeva NA. Adolescent depressions: a view on the problem (by the foreign publications). Psychiatry and psychopharmacotherapy. 2017;19(3):25–34. (In Russ.). eLIBRARY ID: 30281184.

27. Gerstenberg M, Hauser M, Al-Jadiri A, Sheridan EM, Kishimoto T, Borenstein Y, Vernal D, David L, Saito E, Landers SE, Carella M, Singh S, Carbon M, Jiménez–Fernández S, Birnbaum ML, Auther A, Carrión RE, Cornblatt BA, Kane JM, Walitza S, Correll CU. Frequency and correlates of DSM-5 attenuated psychosis syndrome in a sample of adolescent inpatients with nonpsychotic psychiatric disorders. J. Clin. Psychiatry. 2015;76:e1449–1458. https://DOI.org/10.4088/JCP.14m09435

28. van Os J, Guloksuz S. A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry. 2017;16:200–206. https://DOI.org/10.1002/wps.20423

29. McGorry P, Hartmann J, Spooner R, Nelson B. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018;17(2):133–142. https://DOI.org/10.1002/wps.20514

30. Debbané M, Eliez S, Badoud D, Conus P, Flückiger R, Schultze–Lutter F. Developing psychosis and its risk states through the lens of schizotypy. Schizophr. Bull. 2015;41(suppl 2):S396–S40. https://DOI.org/10.1093/schbul/sbu176

31. Carrion RE, Correll CU, Auther AM, Cornblatt BA. A severity-based clinical staging model for the psychosis prodrome: longitudinal findings from the New-York recognition and prevention program. Schizophr. Bull. 2017;43:64–74. https://DOI.org/10.1093/schbul/sbw155

32. Rutigliano G, Valmaggia L, Landi P, Frascarelli M, Cappucciati M, Sear V, Rocchetti M, De Micheli A, Jones C, Palombini E, McGuire P, Fusar-Poli P. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. J. Affect. Disord. 2016;203:101–110. https://DOI.org/10.1016/j.jad.2016.05.053

33. Polari A, Lavoie S, Yuen HP, Amminger P, Berger G, Chen E, deHaan L, Hartmann J, Markulev C, Melville F, Nieman D, Nordentoft M, Riecher-Rössler A, Smesny S, Stratford J, Verma S, Yung A, McGorry P, Nelson B. Clinical trajectories in the ultra-high risk for psychosis population. Schizophr. Res. 2018;197:550–556. https://DOI.org/10.1016/j.schres.2018.01.022

34. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am. J. Psychiatry. 2015;172:249–258. https://DOI.org/10.1176/appi.ajp.2014.13030418

35. Smulevich AB, Muhorina AK, Voronova EI, Romanov DV. Modern concepts of negative disorders in schizophrenia and schizophrenic spectrum disorders. Psychiatry. 2016;4(72):5–19. (In Russ.). eLIBRARY ID: 29384079

36. Barkhatova AN. Prognostic importance of the psychopathological remission structure at the initial stage of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):5–11 (In Russ.). https://DOI.org/10.17116/jnevro20191190315

37. Oliver D, Reilly TJ, Baccaredda BO, Petros N, Davies C, Borgwardt S, McGuire P, Fusar-Poli P. What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. Schizophr. Bull. 2020;46(1):110–120. https://DOI.org/10.1093/schbul/sbz039

38. Piskulic D, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, McGlashan TH. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012;196(2–3):220–224. https://DOI.org/10.1016/j.psychres.2012.02.018

39. Lee TY, Lee J, Kim M, Choe E1, Kwon JS. Can we predict psychosis outside the clinical high-risk state? A systematic review of non-psychotic risk syndromes for mental disorders. Schizophr. Bull. 2018;44:276-85. https://DOI.org/10.1093/schbul/sbx173

40. Smulevich AB. Briko NI, Andryushchenko AV, Romanov DV, Shuliak YuA, Brazhnikov АYu, Gerasimov AN, Melikpashaian AE, Mironova EV, Pushkarev DF. Comorbidity of depression and nonaffective — schizophrenia spectrum disorders: the clinical-epidemiological study EDIP. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2015;115:11(2):6–19. (In Russ.). eLIBRARY ID: 25418317

41. Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, Rosen M, Ruef A, Dwyer DB, Paolini M, Chisholm K, Kambeitz J, Haidl T, Schmidt A, Gillam J, Schultze-Lutter F, Falkai P, Reiser M, Riecher-Rössler A, Upthegrove R, Hietala J, Salokangas RKR, Pantelis C, Meisenzahl E, Wood SJ, Beque D, Brambilla P, Borgwardt S. PRONIA Consortium. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry. 2018;75(11):1156–1172. https://DOI.org/10.1001/jamapsychiatry.2018.2165

42. Ajnakina O. First episode psychosis: looking backwards and forwards. London: King’s College London, 2017. https://kclpure.kcl.ac.uk/portal/files/64380968/2017_Ajnakina_Olesya_1113069_ethesis.pdf

43. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P. Preventing a first episode ofpsychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr. Res. 2013;149:56–62. https://DOI.org/10.1016/j.schres.2013.07.004

44. Brummit K, Addington J. Treatment possibilities for individuals at clinical high risk of psychosis. Early Interv Psychiatry. (2014)7(2):155–161. https://DOI.org/10.1111/j.1751-7893.2012.00370.x

45. Borsboom D, Cramer A, Kalis A. Brain disorders? Not really… Why network structures block reductionism in psychopathology research. Behav. Brain Sci. 2018;24:1–54. https://DOI.org/10.1017/S0140525X17002266

46. Davies C, Radua J, Cipriani A, Stahl D, Provenzani U, McGuire P, Fusar-Poli P. Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis. Front Psychiatry. 2018;9:187. https://DOI.org/10.3389/fpsyt.2018.00187

47. Taylor M, Perera U. NICE CG178 psychosis and schizophrenia in adults: Treatment and management — an evidence-based guideline? Br. J. Psychiatry. 2015;206:357–359 https://DOI.org/10.1192/bjp.bp.114.155945

48. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013;346:f185.10.1136/bmj.f762

49. Bykowsky O, Harrisberger F, Schmidt A, Smieskova R, Hauke DJ, Egloff L, Riecher-Rössler A, Fusar-Poli P, Huber CG, Lang UE, Andreou C, Borgwardt S. Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. Sci. Rep. 2019;9(1):8516. https://DOI.org/10.1038/s41598-019-44903-y

50. Hatton SN, Lagopoulos J, Hermens DF, Scott E, Hickie IB, Bennett MR. Cortical thinning in young psychosis and bipolar patients correlate with common neurocognitive deficits. International Journal of Bipolar Disorders. 2013;1(1):1–13. https://DOI.org/10.1186/2194-7511-1-3

51. Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. J. Affect. Disord. 2015;180:179–184. https://DOI.org/10.1016/j.jad.2015.03.021

52. Davis J, Moylan S, Harvey BH, Maes M, Berk M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust. NZ J. Psychiatry. 2014;48:512–529. https://DOI.org/10.1177/0004867414533012

53. Bolu A, Aydın MS, Akgün A, Coşkun A, Garip B, Öznur T, Çelik C, Uzun Ö. Serum Levels of High Sensitivity C-reactive Protein in Drug-naÏve First-episode Psychosis and Acute Exacerbation of Schizophrenia. Clin. Psychopharmacol Neurosci. 2019;17(2):244–249. https://DOI.org/10.9758/cpn.2019.17.2.244

54. Hong J, Bang M. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clin. Psychopharmacol. Neurosci. 2020;18(1):10–24. https://DOI.org/10.9758/cpn.2020.18.1.10

55. Dyall SC. Long-chain ome ga-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front. Aging. Neurosci. 2015;7:52. https://DOI.org/10.3389/fnagi.2015.00052

56. Amminger GP, Berger M, Rice SM, Davey CG, Schafer MR, Mcgorry PD. Novel biotherapies are needed in youth mental health. Australia Psychiatry. 2017425:117–20. https://DOI.org/10.1177/1039856217698237

57. Berger M, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, McGorry PD, Amminger GP. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO. Clinical Trial. Front Psychiatry. 2019;10:393. https://DOI.org/10.3389/fpsyt.2019.00393

58. Goulding S, Holtzman C, Trotman H,Ryan A, MacDonald A, Shapiro D, Brasfield J, Walker E. The Prodrome and Clinical Risk for Psychotic Disorders. Child Adolesc. Psychiatr Clin. N. Am. 2013;22(4):557–567. https://DOI.org/10.1016/j.chc.2013.04.002

59. Schmidt A, Smieskova R, Simon A, Allen P, Fusar-Poli P, McGuire PK, Bendfeldt K, Aston J, Lang UE, Walter M, Radue EW, Riecher-Rössler A, Borgwardt SJ. Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. J. Psychiatry Neurosci. 2014;39(4):239–248. https://DOI.org/10.1503/jpn.130102

60. Demchyeva NK, Kazakhovtzev BA, Mikhailov VI. Formation, clinic and dynamic of negative symptomatic of the initial stage of schizophrenia. Vestnik nevrologii psihiatrii i neyrohirurgii. 2015;10:13–20. (In Russ.). eLIBRARY ID:28765869

61. Omelchenko MA. Negative symptoms at the prodromal stage of schizophrenia at a young age (current problems of diagnostics and treatment). V.M. Bekhterev review of psychiatry and medical psychology. 2019;(4–2):41–48. (In Russ.). https://DOI.org/10.31363/2313-7053-2019-4-2-41-48.

62. Deas G, Kelly C, Hadjinicolaou AV, Holt C, Agius M, Zaman R. An update on: meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at risk mental states. Psychiatr. Danub. 2016;28:31–38. PMID:27663802